ITGAX and cancer: Takahashi et al. divided DCs into two functionally heterogeneous subgroups: DC1 (CD11c+ DCs, known as myeloid DCs, which stimulate naïve T cells to protect against cancer) and DC2 (CD11c− DCs, known as lymphoid DCs, which activate Th2 cells which generate IL-4) [14].